ViennaLab Diagnostics is part of the HUFIAT Consortium awarded a contract for Phase 1 to develop an end-to-end NGS solution in the field of liquid biopsy (cfDNA).
ViennaLab Diagnostics will apply their expertise in cfDNA and genetic tests and join forces with bioinformatics experts – Euformatics and AI specialists – Oncompass Medicine to work on a solution which aims to improve the field of liquid biopsy and cancer detection.
With this non-invasive approach we will develop a Pan-cancer cfDNA test to profile the tumor landscape which will allow to predict the best personalized treatment for every patient.
Follow the link to get more information on OncNGS . Please click here for the official Press Release.